ArticleTissue engineering. Part C, Methods2012
Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen.
Article in Tissue engineering. Part C, Methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05711355 (A Randomized Trial of the Effects of Platelet-Rich Plasma on Postoperative Complications After Meningomyelocele Sac Repair), which is not on this map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial of the Effects of Platelet-Rich Plasma on Postoperative Complications After Meningomyelocele Sac Repair
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.
- The potential of platelet-rich plasma and PRP-derived biologics for neurological disorders: mechanisms and translational research.Frontiers in immunology · 2026Pooled it
- Effects of Nanofat and PRP on Type I Collagen Production in Striae Distensae: Preliminary Findings from a Prospective, Randomized Single-Blind Study.Aesthetic plastic surgery · 2025Trial
- Clinical use of Plasma Protein from Platelet in Degenerative Joint Disease: A Prospective Study.Journal of orthopaedic case reports · 2022Trial
- Three injections of freeze-dried platelet factor concentrate provide greater clinical response than single injection in the treatment of knee osteoarthritis.Journal of experimental orthopaedics · 2026Article
- Are Platelet Volume, Density, and the Homeostatic Blueprint the Missing Link in Platelet-Rich Plasma Therapies? An Evidence-Based Narrative Review.Journal of clinical medicine · 2026Review
- Article
- Article
- Standardization of canine platelet-rich plasma preparation and its functional characterization.Journal of veterinary science · 2026Article
- Clinical outcome of adding injection of freeze-dried platelet-derived factor concentrate to operative treatment accompanied by an early rehabilitation for Achilles tendon rupture in high-level athletes.Regenerative therapy · 2025Article
- Article
- Enhancing the Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells for Osteoarthritis: The Role of Platelet-Rich Plasma and Extracellular Vesicles.International journal of molecular sciences · 2025Article
- Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease.Ophthalmology and therapy · 2025Article
- Differences between first- and second-generation autologous platelet concentrates.Periodontology 2000 · 2025Review
- Comparison of bioactive substances in novel-developed freeze-dried platelet-rich plasma (PRP) and activated normal PRP, and investigation of bioactive substance levels after long-term storage.Regenerative therapy · 2024Article
- Reply: Comparison of Two Anticoagulants for Pain Associated with Platelet-Rich Plasma Injections.Aesthetic plastic surgery · 2024Article
- Optimization of Platelet-Rich Plasma Preparation for Regenerative Medicine: Comparison of Different Anticoagulants and Resuspension Media.Bioengineering (Basel, Switzerland) · 2024Article
- Growth factor and cytokine characterization of canine platelet lysate with variable leukocyte concentration, plasma content, and heat-sensitive proteins.Frontiers in veterinary science · 2024Article
- Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies.BioMed research international · 2024Review
- Freeze-dried noncoagulating platelet-derived factor concentrate is a safe and effective treatment for early knee osteoarthritis.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2023Article
- Optimizing Platelet-Rich Plasma: Spin Time and Sample Source.Bioengineering (Basel, Switzerland) · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP) has been clinically used as an easily prepared growth factor cocktail that can promote wound healing, angiogenesis, and tissue remodeling. However, the therapeutic effects of PRP are still controversial, due partly to the lack of optimized and standardized preparation protocols. We used whole blood (WB) samples to optimize the preparation protocols for PRP, white blood cell-containing (W-PRP), platelet-concentrated plasma (PCP), and noncoagulating platelet-derived factor concentrate (PFC). PRP and W-PRP were most efficiently collected by 10 min centrifugation in a 15-mL conical tube at 230-270 g and 70 g, respectively. To prepare PCP, platelets were precipitated by centrifugation of PRP at >2300 g, 90% of supernatant plasma was removed, and the platelets were resuspended. For preparation of noncoagulating PFC, the supernatant was replaced with one-tenth volume of saline, followed by platelet activation with thrombin. Platelet (before activation) and platelet-derived growth factor (PDGF)-BB (after activation) concentrations in PCP were approximately 20 times greater than those in WB, whereas PFC contained a 20-times greater concentration of platelets before platelet activation and a 50-times greater concentration of PDGF-BB without formation of a fibrin gel after platelet activation than WB. Surprisingly, total PDGF-BB content in the PFC was twice that of activated WB, which suggested that a substantial portion of the PDGF-BB became trapped in the fibrin glue, and replacement of plasma with saline is crucial for maximization of platelet-derived factors. As an anticoagulant, ethylene di-amine tetra-acetic acid disodium inhibited platelet aggregation more efficiently than acid citrate dextrose solution, resulting in higher nonaggregated platelet yield and final PDGF-BB content. These results increase our understanding of how to optimize and standardize preparation of platelet-derived factors at maximum concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.